CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $356,019 | +89.4% | 11,971 | +14.8% | 0.00% | 0.0% |
| Q2 2023 | $187,967 | -8.5% | 10,431 | -7.0% | 0.00% | 0.0% |
| Q4 2022 | $205,363 | +0.7% | 11,222 | +8.9% | 0.00% | 0.0% |
| Q3 2022 | $204,000 | +8.5% | 10,309 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $188,000 | -36.9% | 10,079 | -25.7% | 0.00% | 0.0% |
| Q1 2022 | $298,000 | -37.4% | 13,559 | -19.1% | 0.00% | 0.0% |
| Q4 2021 | $476,000 | +73.7% | 16,755 | +28.5% | 0.00% | 0.0% |
| Q3 2021 | $274,000 | -10.5% | 13,034 | -19.6% | 0.00% | 0.0% |
| Q2 2021 | $306,000 | +70.0% | 16,217 | +37.6% | 0.00% | 0.0% |
| Q1 2021 | $180,000 | +15.4% | 11,786 | +6.4% | 0.00% | 0.0% |
| Q4 2020 | $156,000 | -24.6% | 11,075 | +21.7% | 0.00% | 0.0% |
| Q1 2019 | $207,000 | -22.2% | 9,098 | +2.4% | 0.00% | -50.0% |
| Q4 2018 | $266,000 | – | 8,881 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |